WHO WE ARE

As a mid-sized global biopharmaceutical company, Ipsen improves patients’ lives through research, innovation and the development of transformative medicines in Oncology, Rare Disease and Neuroscience.

WHAT WE DO

WHAT WE DO

Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to patients.

Author Image

Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs. We’re leveraging the full force of Ipsen’s infrastructure, innovation and passion to develop new therapies and valuable collaborations.

David Loew

CEO

 

PATIENTS

Putting patients at the heart of our work

Our commitment to improving the lives and medical outcomes of patients is the driving force behind every decision made at Ipsen. We believe in working with patients, for patients, listening to their needs and involving their insights in the entire.

RESPONSIBILITY

RESPONSIBILITY

Shaping a more sustainable future

Ipsen is dedicated to safeguarding and preserving our planet. The Generation Ipsen ESG responsibility strategy lays out ambitious goals for the company in each of four pillars: Environment, Patients, People and Governance.

Careers at Ipsen

Ipsen offers a multitude of exciting opportunities for talented and motivated people in careers ranging from medial and clinical research to sales, marketing, finance, IT, HR and legal services. We are committed to providing our employees with a workplace that is welcoming, challenging and inclusive.

Top Ipsen stories

29 November 2023 1 mins read
‘Get men talking’: breaking the silence around prostate cancer

Tim Batchelor, Ipsen’s Head of Global Commercial Learning & Development, candidly shares his experience of living with prostate cancer. At the age of 48, Tim was confronted with a prostate cancer diagnosis. His early detection proved pivotal, leading to successful…

28 November 2023 2 mins read
Primary Biliary Cholangitis: The Power of Patient Reported Outcomes

“The important thing with PBC is to take a holistic view of it, and think ‘What are the problems we are trying to solve? The first is the risk of progression to cirrhosis, and the other is symptoms and quality…

20 November 2023 1 mins read
Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics

Starting now and throughout 2024, Ipsen is sponsoring five talented, elite athletes on their journeys toward the 2024 Paralympic Games.

13 November 2023 1 mins read
The Liver Meeting 2023: Innovating for people living with rare liver diseases

Jennifer Schranz (Ipsen’s Global Head of Rare Diseases) attended The Liver Meeting from November 10-14, sharing key insights from her time onsite and explaining why scientific congresses are vital in helping advance innovation for patients. 

10 November 2023 2 mins read
Ipsen’s mission to accelerate innovation in oncology

The outputs from the European Society of Medical Oncology (ESMO) Congress this year encompassed several important new data announcements, highlighting key advances in the development of therapies for people living with cancer.  However, cancer remains a formidable global health challenge,…

10 November 2023 1 mins read
Examining the European Pharma legislation: EFPIA publishes the Dolon Report

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact of the proposed European Commission pharma legislation. The Dolon Report, published on 6 November, has projected that the proposed legislation…

03 November 2023 0 mins read
Capital Markets Day 2023

Ipsen plans to host a capital-markets day, starting at 12.30 pm GMT on 7 December 2023, at The Brewery, London. In-person attendance is by invitation only.

31 October 2023 2 mins read
Ipsen stands together to make innovation in rare disease happen

Developing innovation for people living with rare diseases is uniquely challenging. It requires all the different pieces of the puzzle– clinical viability, economic viability and the policy environment— to come together before innovation can reach patients.

31 October 2023 2 mins read
Innovating for people living with primary biliary cholangitis

At Ipsen we have been focused on developing new and innovative treatments for rare diseases for many years in endocrinology, rare bone disease and more recently in rare liver disease. This focus continues to be a core part of our…

29 October 2023 1 mins read
Rising to the challenge, life after stroke

Globally, stroke is the 2nd leading cause of death worldwide, in addition to being the 3rd leading cause of combined death and disability across the world, with approximately 1 in 4 people over the age of 25 expected to experience…